Perindopril for the treatment of hypertension

Bibliography

• Lopez AD, Mathers CD, Ezzati M, Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2002;360:1347-60
   PubMedGoogle Scholar
• Ezzati M, Lopez AD, Rodgers A, Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-60
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K, Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, De Backer G, for the EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009;373:929-40
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
   PubMed Web of Science ®Google Scholar
• Collins R, Peto R, MacMahon S, Blood pressure, stroke, and coronary heart disease. Part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38
   PubMed Web of Science ®Google Scholar
• Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, 2007 Guidelines for the Management of Arterial Hypertension: the task force for the management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58
   PubMed Web of Science ®Google Scholar
• Reid IA. The renin-angiotensin system and body function. Arch Intern Med 1985;145:1475
   PubMedGoogle Scholar
• Dzau VJ. Mechanism of action of angiotensin-converting enzyme (ACE) inhibitors in hypertension and heart failure. Role of plasma versus tissue ACE. Drugs 1990;39( Suppl 2):11-16
   PubMedGoogle Scholar
• Yusuf S, Teo KK, Pogue J, ONTARGET Investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR, ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366:895-906
   PubMed Web of Science ®Google Scholar
• Beckett NS, Peters R, Fletcher AE, HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-98
   PubMed Web of Science ®Google Scholar
• ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE Trial): a randomised controlled trial. Lancet 2007;370:829-40
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41
   PubMed Web of Science ®Google Scholar
• Fox KM; EURopean trial On reduction of cardiac events with perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8
   PubMed Web of Science ®Google Scholar
• Vincent M, Marchand B, Richmond G, Synthesis and ACE inhibitory activity of the stereoisomers of perindopril (S 9490) and perindoprilate (S 9780). Drug Des Discov 1992;9:11-28
   PubMedGoogle Scholar
• Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998;97:1411-20
   PubMed Web of Science ®Google Scholar
• Telejko E. Perindopril arginine: benefits of a new salt of the ACE inhibitor perindopril. Curr Med Res Opin 2007;23:953-60
   PubMed Web of Science ®Google Scholar
• Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-54
   PubMed Web of Science ®Google Scholar
• Gainer JV, Morrow JD, Loveland A, Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1285-92
   PubMed Web of Science ®Google Scholar
• Vanhoutte PM. Endothelial dysfunction and inhibition of converting enzyme. Eur Heart J 1998;19( Suppl J):J7-15
   PubMedGoogle Scholar
• Comini L, Bachetti T, Cargnoni A, Therapeutic modulation of the nitric oxide: all ace inhibitors are not equivalent. Pharmacol Res 2007;56:42-8
   PubMed Web of Science ®Google Scholar
• Zhuo JL, Mendelsohn FA, Ohishi M. Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 2002;39(2 Pt 2):634-8
   PubMedGoogle Scholar
• Ceconi C, Francolini G, Olivares A, Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol 2007;577:1-6
   PubMed Web of Science ®Google Scholar
• Johnston CI, Fabris B, Yamada H, Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens 1989;7( Suppl 5):S11-16
   Google Scholar
• Devissaguet JP, Ammoury N, Devissaguet M, Pharmacokinetics of perindopril and its metabolites in healthy volunteers. Fundam Clin Pharmacol 1990;4:175-89
   PubMed Web of Science ®Google Scholar
• Alfakih K, Hall AS. Perindopril. Expert Opin Pharmacother 2006;7:63-71
   PubMed Web of Science ®Google Scholar
• Verpooten GA, Genissel PM, Thomas JR, Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency. Br J Clin Pharmacol 1991;32:187-92
   PubMed Web of Science ®Google Scholar
• Louis WJ, Conway EL, Krum H, Comparison of the pharmacokinetics and pharmacodynamics of perindopril, cilazapril and enalapril. Clin Exp Pharmacol Physiol Suppl 1992;19:55-60
   PubMedGoogle Scholar
• Salvetti A. Newer ACE inhibitors. A look at the future. Drugs 1990;40:800-28
   PubMedGoogle Scholar
• Salvetti A, Di Venanzio L, Arrighi P, Throuht: peak ratio of the blood pressure response to angiotensin converting enzyme inhibitors. J Hypertens 1994;12( Suppl 8):S91-5
   Google Scholar
• Lecocq B, Funck-Brentano C, Lecocq V, Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum. Clin Pharmacol Ther 1990;47:397-402
   PubMedGoogle Scholar
• Thiollet M, Funck-Brentano C, Grande JD, The pharmacokinetics of perindopril in patients with liver cirrhosis. Br J Clin Pharmacol 1992;33:326-8
   PubMed Web of Science ®Google Scholar
• Hurst M. Jarvis B Perindopril: an updated review of its use in hypertension. Drugs 2001;61:867-96
   PubMed Web of Science ®Google Scholar
• Taddei S, Bruno RM, Ghiadoni L. The correct administration of antihypertensive drugs according to the principles of clinical pharmacology. Am J Cardiovasc Drugs 2011;11:13-20
   PubMed Web of Science ®Google Scholar
• Myers MG. A dose-response study of perindopril in hypertension: effects of blood pressure 6 and 24 h after dosing. Perindopril Multicentre Dose-Response Study Group. Can J Cardiol 1996;12:1191-6
   PubMed Web of Science ®Google Scholar
• Morgan T, Anderson A. How important is 24-hour control of blood pressure? Drug Saf 1996;15:243-8
   PubMedGoogle Scholar
• Morgan T. Twenty four hour BP control-which is best, throught:peack ratios or ABPM? Br J Cardiol 1995;2(Suppl 1):S7-9
   Google Scholar
• Julius S, Cohn JN, Neutel J, Antihypertensive utility of perindopril in a large, general practice-based clinical trial. J Clin Hypertens (Greenwich) 2004;6:10-17
   PubMedGoogle Scholar
• Poggi L, Renucci JF, Denolle T. Tratment of essential hypertension in general practice: an open-label study of 47 351 French hypertensive patients treated for one year with perindopril. Can J Cardiol 1994;10( Suppl D):21D-24D
   Google Scholar
• Speirs C, Wagniart F, Poggi L. Perindopril post-marketing surveillance: a 12 month study in 14,351 hypertensive patients. Br J Clin Pharmacol 1998;46:63-70
   PubMed Web of Science ®Google Scholar
• Ionescu DD; on behalf of the PREFER investigators. Antihypertensive efficacy of perindopril 5-10 mg in primary health care. Clin Drug Investig 2009;29:767-76
   PubMedGoogle Scholar
• Tsoukas G, Tsoukas G, Anand S, Yang K; CONFIDENCE Investigators. Dose-dependent antihypertensive efficacy and tolerability of perindopril in a large, observational, 12-week, general practice-based study. Am J Cardiovasc Drugs 2011;11(1):45-55
   PubMed Web of Science ®Google Scholar
• Rothwell Howard SC, Dolan E, Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010;375:895-905
   PubMedGoogle Scholar
• Rothwell PM, Howard SC, Dolan E, ASCOT-BPLA and MRC Trial Investigators. Effects of beta-blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010;9:469-80
   PubMed Web of Science ®Google Scholar
• Williams B, Lacy PS, Thom SM, CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-25
   PubMed Web of Science ®Google Scholar
• Asmar RG, London GM, O'Rourke ME, on behalf of REASON Project Coordinators and Investigators. Improvement in blood pressure, arterial stiffness and wave reflection with a very-low-dose perindopril/indapamide combination in hypertensive patients: a comparison with atenolol. Hypertension 2001;38:922-6
   PubMed Web of Science ®Google Scholar
• de Luca N, Asmar RG, London GM, REASON Project Investigators. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. J Hypertens 2004;22:1623-30
   PubMed Web of Science ®Google Scholar
• Vlachopoulos C, Aznaouridis K, O'Rourke MF, Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010;31:1865-71
   PubMed Web of Science ®Google Scholar
• Ghiadoni L, Bruno RM, Stea F, Central blood pressure, arterial stiffness, and wave reflection: new targets of treatment in essential hypertension. Curr Hypertens Rep 2009;11:190-6
   PubMed Web of Science ®Google Scholar
• Laurent S. Evidence for benefits of perindopril in hypertension and its complications. Am J Hypertens 2005;18:155S-162S
   Web of Science ®Google Scholar
• Tropeano AI, Boutouyrie P, Pannier B, Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 2006;48:80-6
   PubMed Web of Science ®Google Scholar
• Guerin AP, Blacher J, Pannier B, Impact ofaortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001;103:987-92
   PubMed Web of Science ®Google Scholar
• Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005;111:363-8
   PubMed Web of Science ®Google Scholar
• Rizzoni D, Porteri E, Boari GE, Prognostic significance of small-artery structure in hypertension. Circulation 2003;108:2230-5
   PubMed Web of Science ®Google Scholar
• Ghiadoni L, Magagna A, Versari D, Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003;41:1281-6
   PubMed Web of Science ®Google Scholar
• Ghiadoni L, Magagna A, Kardasz I, Fixed dose combination of perindopril and indapamide improves peripheral vascular function in essential hypertensive patients. Am J Hypertens 2009;22:506-12
   PubMed Web of Science ®Google Scholar
• Thybo NK, Stephens N, Cooper A, Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995;25(4 Pt 1):474-81
   PubMed Web of Science ®Google Scholar
• Adler A, Stratton IM, Neil H, Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes: UKPDS 36. Prospective observational study. BMJ 2000;321:412-19
   PubMed Web of Science ®Google Scholar
• Ghiadoni L. Management of high blood pressure in type 2 diabetes: perindopril/indapamide fixed-dose combination and the ADVANCE trial [corrected]. Expert Opin Pharmacother 2010;11:1647-57. Erratum in: Expert Opin Pharmacother 2010;11;1963
   PubMed Web of Science ®Google Scholar
• de Galan BE, Perkovic V, Ninomiya T, ; ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009;20:883-9
   PubMed Web of Science ®Google Scholar
• Dagenais GR, Pogue J, Fox K, Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581-8
   PubMed Web of Science ®Google Scholar
• Brugts JJ, Ninomiya T, Boersma E, The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J 2009;30:1385-9
   PubMedGoogle Scholar
• Mourad JJ, Bertrand M. Impact of antihypertensive treatment on mortality: a late – break analysis of recent clinical trials in hypertension [abstract]. J Hypertens 2010;28(e-Suppl A):e396
   Google Scholar
• Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. Am J Med 2010;123:1016-30
   PubMed Web of Science ®Google Scholar
• Clark LT. Safety profile of perindopril. Am J Cardiol 2001;88(7A):36i-40i
   Google Scholar
• Brugts JJ, Isaacs A, de Maat MP, A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. J Hypertens 2011;29:509-19
   PubMed Web of Science ®Google Scholar